- Home
- ACEL vs URGN Comparison
ACEL vs URGN Comparison
Compare ACEL & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACEL
- URGN
- Stock Information
- Founded
- ACEL 2009
- URGN 2004
- Country
- ACEL United States
- URGN United States
- Employees
- ACEL N/A
- URGN N/A
- Industry
- ACEL Services-Misc. Amusement & Recreation
- URGN Biotechnology: Pharmaceutical Preparations
- Sector
- ACEL Consumer Discretionary
- URGN Health Care
- Exchange
- ACEL Nasdaq
- URGN Nasdaq
- Market Cap
- ACEL 934.8M
- URGN 830.4M
- IPO Year
- ACEL N/A
- URGN 2017
- Fundamental
- Price
- ACEL $10.48
- URGN $18.03
- Analyst Decision
- ACEL Buy
- URGN Strong Buy
- Analyst Count
- ACEL 1
- URGN 8
- Target Price
- ACEL $16.00
- URGN $28.50
- AVG Volume (30 Days)
- ACEL 302.9K
- URGN 1.1M
- Earning Date
- ACEL 11-04-2025
- URGN 11-05-2025
- Dividend Yield
- ACEL N/A
- URGN N/A
- EPS Growth
- ACEL N/A
- URGN N/A
- EPS
- ACEL 0.40
- URGN N/A
- Revenue
- ACEL $1,279,563,000.00
- URGN $94,238,000.00
- Revenue This Year
- ACEL $9.91
- URGN $39.63
- Revenue Next Year
- ACEL $4.73
- URGN $111.49
- P/E Ratio
- ACEL $26.15
- URGN N/A
- Revenue Growth
- ACEL 7.00
- URGN 10.85
- 52 Week Low
- ACEL $9.02
- URGN $3.42
- 52 Week High
- ACEL $13.28
- URGN $21.71
- Technical
- Relative Strength Index (RSI)
- ACEL 42.19
- URGN 53.26
- Support Level
- ACEL $10.24
- URGN $16.37
- Resistance Level
- ACEL $10.51
- URGN $17.64
- Average True Range (ATR)
- ACEL 0.25
- URGN 0.90
- MACD
- ACEL -0.01
- URGN 0.10
- Stochastic Oscillator
- ACEL 31.31
- URGN 90.80
About ACEL Accel Entertainment Inc.
Accel Entertainment Inc is a distributed gaming and local entertainment operator in the United States. It is engaged in the installation, maintenance, operation, and servicing of gaming terminals and related equipment, redemption devices that disburse winnings and contain automated teller machine (ATM) functionality, and amusement devices in authorized non-casino locations such as restaurants, bars, taverns, convenience stores, liquor stores, truck stops, and grocery stores. The Company also operates stand-alone ATMs in gaming and non-gaming locations. It generates revenue from Net gaming, Amusement, Manufacturing, ATM fees, and others.
About URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.